Avanzini F, Alli C, Bettelli G, Corso R, Colombo F, Mariotti G, Radice M, Torri V, Tognoni G
Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.
Eur Heart J. 1994 Feb;15(2):206-12. doi: 10.1093/oxfordjournals.eurheartj.a060477.
The pharmacological treatment, mainly based on diuretics, of isolated systolic hypertension (ISH) has recently been shown to reduce the risk of stroke and coronary heart disease in the elderly. The purpose of this study was to compare the antihypertensive effect and tolerability of different drug regimens in elderly subjects with ISH (systolic blood pressure--SBP-- > or = 160 mmHg and diastolic blood pressure--DBP-- < 90 mmHg). A multicentre, randomized, controlled open trial was planned in the general practice setting. Four widely used treatment schedules were tested: hydrochlorothiazide 25 mg plus amiloride 2.5 mg (H+Am), nifedipine slow release 20 mg (N), atenolol 50 mg (At) and atenolol 25 mg plus chlorthalidone 6.25 mg (At+C). After a baseline evaluation, 308 patients (76.3% female, mean age 75.3 +/- 7.1 years) were randomized and followed up for 6 months. After 3 months the drug dosage was doubled if the systolic blood pressure goal (SBP < 160 mmHg and SBP reduction of at least 20 mmHg) had not been reached. Ninety-four subjects (30.5%) presented contraindications to beta-blockers. At the 3rd- and 6th-month visits all treatment groups, except At, showed a significant reduction in SBP compared to the control group; DBP showed no significant reduction in any group at any time. At the end of the follow-up the percentage of hypertensives who had reached the BP goal was 14.6% in the control group, 52.9% in H+Am, 54.8% in N, 28.6% in At and 52.2% in At+C.(ABSTRACT TRUNCATED AT 250 WORDS)
以利尿剂为主的单纯收缩期高血压(ISH)药物治疗最近已被证明可降低老年人中风和冠心病的风险。本研究的目的是比较不同药物治疗方案对ISH老年患者(收缩压——SBP——≥160 mmHg且舒张压——DBP——<90 mmHg)的降压效果和耐受性。在全科医疗环境中计划进行一项多中心、随机、对照开放试验。测试了四种广泛使用的治疗方案:氢氯噻嗪25 mg加阿米洛利2.5 mg(H+Am)、硝苯地平缓释片20 mg(N)、阿替洛尔50 mg(At)以及阿替洛尔25 mg加氯噻酮6.25 mg(At+C)。经过基线评估后,308例患者(女性占76.3%,平均年龄75.3±7.1岁)被随机分组并随访6个月。3个月后,如果未达到收缩压目标(SBP<160 mmHg且SBP降低至少20 mmHg),则将药物剂量加倍。94名受试者(30.5%)存在β受体阻滞剂禁忌证。在第3个月和第6个月访视时,除At组外,所有治疗组的SBP与对照组相比均显著降低;任何组在任何时间的DBP均未显示出显著降低。随访结束时,对照组高血压患者达到血压目标的百分比为14.6%,H+Am组为52.9%,N组为54.8%,At组为28.6%,At+C组为52.2%。(摘要截断于250字)